Kevin Sexton
Concepts (332)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Wounds and Injuries | 9 | 2022 | 321 | 2.240 |
Why?
| Venous Pressure | 4 | 2021 | 20 | 1.550 |
Why?
| Trauma Centers | 12 | 2022 | 218 | 1.270 |
Why?
| General Surgery | 4 | 2018 | 113 | 1.160 |
Why?
| Resuscitation | 4 | 2022 | 83 | 0.960 |
Why?
| Thrombelastography | 2 | 2021 | 28 | 0.920 |
Why?
| Surgical Procedures, Operative | 2 | 2021 | 78 | 0.920 |
Why?
| Triage | 2 | 2022 | 76 | 0.850 |
Why?
| Wounds, Penetrating | 2 | 2021 | 41 | 0.850 |
Why?
| Hemorrhage | 3 | 2022 | 208 | 0.830 |
Why?
| Air Ambulances | 2 | 2018 | 27 | 0.820 |
Why?
| Verapamil | 1 | 2021 | 23 | 0.790 |
Why?
| Retrospective Studies | 24 | 2023 | 6432 | 0.780 |
Why?
| Clinical Competence | 5 | 2020 | 446 | 0.780 |
Why?
| Aneurysm, Ruptured | 1 | 2021 | 20 | 0.770 |
Why?
| Vasospasm, Intracranial | 1 | 2021 | 17 | 0.770 |
Why?
| Measles | 1 | 2020 | 9 | 0.770 |
Why?
| Education, Medical, Graduate | 3 | 2018 | 225 | 0.760 |
Why?
| Intracranial Aneurysm | 1 | 2021 | 54 | 0.750 |
Why?
| Vasodilator Agents | 1 | 2021 | 111 | 0.740 |
Why?
| Subarachnoid Hemorrhage | 1 | 2021 | 65 | 0.740 |
Why?
| Models, Statistical | 1 | 2021 | 259 | 0.730 |
Why?
| Humans | 60 | 2023 | 54284 | 0.720 |
Why?
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 28 | 0.700 |
Why?
| Brain Ischemia | 1 | 2021 | 169 | 0.690 |
Why?
| Vital Signs | 1 | 2019 | 19 | 0.690 |
Why?
| Health Literacy | 1 | 2021 | 141 | 0.670 |
Why?
| Wavelet Analysis | 1 | 2018 | 7 | 0.650 |
Why?
| Time Factors | 7 | 2021 | 3213 | 0.640 |
Why?
| Blood Pressure Determination | 1 | 2018 | 51 | 0.630 |
Why?
| Injury Severity Score | 5 | 2022 | 178 | 0.620 |
Why?
| Competency-Based Education | 1 | 2017 | 22 | 0.610 |
Why?
| Nerve Regeneration | 3 | 2016 | 24 | 0.600 |
Why?
| Heart Failure | 1 | 2023 | 541 | 0.600 |
Why?
| Operative Time | 1 | 2017 | 76 | 0.600 |
Why?
| Accreditation | 1 | 2017 | 72 | 0.590 |
Why?
| Sciatic Neuropathy | 3 | 2015 | 7 | 0.580 |
Why?
| Risk Assessment | 1 | 2021 | 1361 | 0.570 |
Why?
| Polyethylene Glycols | 3 | 2016 | 106 | 0.570 |
Why?
| Interprofessional Relations | 1 | 2017 | 97 | 0.570 |
Why?
| Abdominoplasty | 1 | 2014 | 3 | 0.510 |
Why?
| Albumins | 1 | 2014 | 38 | 0.510 |
Why?
| Body Fluids | 1 | 2014 | 26 | 0.500 |
Why?
| Gastric Bypass | 1 | 2014 | 22 | 0.500 |
Why?
| Patient Readmission | 5 | 2023 | 242 | 0.490 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 93 | 0.490 |
Why?
| Carcinoma, Merkel Cell | 1 | 2014 | 47 | 0.490 |
Why?
| Male | 27 | 2022 | 27334 | 0.490 |
Why?
| Female | 26 | 2021 | 28441 | 0.480 |
Why?
| Adult | 19 | 2023 | 14207 | 0.470 |
Why?
| Saphenous Vein | 4 | 2016 | 75 | 0.430 |
Why?
| Nerve Transfer | 1 | 2012 | 3 | 0.430 |
Why?
| Surface-Active Agents | 1 | 2012 | 13 | 0.430 |
Why?
| Middle Aged | 16 | 2021 | 13088 | 0.420 |
Why?
| Postoperative Complications | 8 | 2023 | 1033 | 0.420 |
Why?
| Hand Injuries | 3 | 2018 | 24 | 0.410 |
Why?
| Physicians, Women | 1 | 2011 | 24 | 0.400 |
Why?
| Peripheral Nerve Injuries | 3 | 2016 | 26 | 0.400 |
Why?
| Trauma Severity Indices | 3 | 2020 | 57 | 0.400 |
Why?
| Operating Rooms | 3 | 2021 | 40 | 0.390 |
Why?
| Head and Neck Neoplasms | 1 | 2014 | 335 | 0.390 |
Why?
| Faculty, Medical | 1 | 2011 | 100 | 0.370 |
Why?
| Emergency Service, Hospital | 5 | 2020 | 539 | 0.340 |
Why?
| United States | 9 | 2022 | 5217 | 0.340 |
Why?
| Laparoscopy | 2 | 2022 | 188 | 0.340 |
Why?
| Skin Neoplasms | 1 | 2014 | 532 | 0.330 |
Why?
| Free Tissue Flaps | 3 | 2015 | 56 | 0.330 |
Why?
| Treatment Outcome | 9 | 2021 | 5604 | 0.330 |
Why?
| Aged | 12 | 2022 | 10054 | 0.330 |
Why?
| Pyloric Stenosis, Hypertrophic | 2 | 2019 | 29 | 0.330 |
Why?
| Logistic Models | 4 | 2019 | 995 | 0.320 |
Why?
| Respiration, Artificial | 2 | 2022 | 285 | 0.320 |
Why?
| Dehydration | 2 | 2019 | 80 | 0.310 |
Why?
| Anticoagulants | 2 | 2023 | 270 | 0.310 |
Why?
| Health Services Accessibility | 3 | 2018 | 432 | 0.300 |
Why?
| Internship and Residency | 3 | 2018 | 501 | 0.300 |
Why?
| Arkansas | 4 | 2021 | 2100 | 0.290 |
Why?
| Blood Transfusion | 3 | 2022 | 138 | 0.280 |
Why?
| Educational Measurement | 2 | 2018 | 232 | 0.280 |
Why?
| Rural Population | 2 | 2020 | 600 | 0.250 |
Why?
| Neointima | 2 | 2016 | 10 | 0.250 |
Why?
| Vascular Surgical Procedures | 3 | 2018 | 178 | 0.250 |
Why?
| Peripheral Arterial Disease | 2 | 2018 | 88 | 0.240 |
Why?
| Hospitalization | 3 | 2023 | 705 | 0.240 |
Why?
| Pilot Projects | 2 | 2018 | 808 | 0.230 |
Why?
| Sciatic Nerve | 2 | 2014 | 32 | 0.230 |
Why?
| Muscle, Smooth, Vascular | 2 | 2016 | 140 | 0.230 |
Why?
| Swine | 3 | 2021 | 431 | 0.220 |
Why?
| Hospital Mortality | 3 | 2021 | 465 | 0.220 |
Why?
| Antibody Formation | 1 | 2022 | 69 | 0.220 |
Why?
| Hernia, Ventral | 1 | 2022 | 10 | 0.220 |
Why?
| Monitoring, Physiologic | 2 | 2022 | 136 | 0.210 |
Why?
| Venous Thromboembolism | 1 | 2023 | 75 | 0.210 |
Why?
| Insurance Coverage | 2 | 2020 | 107 | 0.210 |
Why?
| Prospective Studies | 3 | 2020 | 2604 | 0.210 |
Why?
| Cholecystitis | 1 | 2021 | 13 | 0.210 |
Why?
| Cholecystostomy | 1 | 2021 | 10 | 0.210 |
Why?
| Cholecystitis, Acute | 1 | 2021 | 11 | 0.210 |
Why?
| Sex Factors | 2 | 2021 | 767 | 0.200 |
Why?
| Patient Discharge | 2 | 2021 | 353 | 0.200 |
Why?
| Names | 1 | 2021 | 9 | 0.200 |
Why?
| Hernia, Inguinal | 1 | 2021 | 19 | 0.200 |
Why?
| Aged, 80 and over | 3 | 2020 | 3431 | 0.200 |
Why?
| Emergency Treatment | 1 | 2021 | 32 | 0.200 |
Why?
| Lorazepam | 1 | 2021 | 13 | 0.200 |
Why?
| Infusions, Intra-Arterial | 1 | 2021 | 18 | 0.200 |
Why?
| Efficiency, Organizational | 2 | 2021 | 53 | 0.200 |
Why?
| Isoflurane | 1 | 2021 | 17 | 0.200 |
Why?
| Cholecystectomy | 1 | 2021 | 32 | 0.200 |
Why?
| Blood Coagulation | 1 | 2021 | 69 | 0.200 |
Why?
| Esophagectomy | 1 | 2021 | 34 | 0.200 |
Why?
| Benchmarking | 1 | 2021 | 73 | 0.200 |
Why?
| Fluid Therapy | 2 | 2019 | 87 | 0.190 |
Why?
| Anesthetics, Inhalation | 1 | 2021 | 35 | 0.190 |
Why?
| Computer Simulation | 2 | 2020 | 332 | 0.190 |
Why?
| Coloring Agents | 3 | 2016 | 84 | 0.190 |
Why?
| ROC Curve | 2 | 2019 | 259 | 0.190 |
Why?
| Propofol | 1 | 2021 | 28 | 0.190 |
Why?
| Bile Ducts | 1 | 2021 | 53 | 0.190 |
Why?
| Measles virus | 1 | 2020 | 9 | 0.190 |
Why?
| Measles Vaccine | 1 | 2020 | 6 | 0.190 |
Why?
| Length of Stay | 5 | 2022 | 683 | 0.190 |
Why?
| Anesthetics | 1 | 2021 | 36 | 0.190 |
Why?
| Cohort Studies | 2 | 2023 | 1543 | 0.190 |
Why?
| Orthopedic Procedures | 1 | 2021 | 82 | 0.190 |
Why?
| Wounds, Nonpenetrating | 1 | 2021 | 91 | 0.190 |
Why?
| Inpatients | 1 | 2022 | 204 | 0.190 |
Why?
| Orthopedics | 1 | 2021 | 54 | 0.190 |
Why?
| Postoperative Care | 1 | 2021 | 121 | 0.190 |
Why?
| Radiography, Thoracic | 1 | 2020 | 69 | 0.190 |
Why?
| Delivery of Health Care | 1 | 2023 | 327 | 0.180 |
Why?
| Esophageal Neoplasms | 1 | 2021 | 100 | 0.180 |
Why?
| Drug Utilization | 1 | 2020 | 74 | 0.180 |
Why?
| Arthroscopy | 1 | 2020 | 57 | 0.180 |
Why?
| Anticonvulsants | 1 | 2021 | 129 | 0.180 |
Why?
| Endothelium, Vascular | 2 | 2012 | 288 | 0.180 |
Why?
| Curriculum | 3 | 2018 | 429 | 0.180 |
Why?
| Animals | 10 | 2021 | 14385 | 0.180 |
Why?
| Pandemics | 2 | 2021 | 579 | 0.180 |
Why?
| Benzenesulfonates | 2 | 2016 | 12 | 0.170 |
Why?
| Insurance, Health | 1 | 2020 | 132 | 0.170 |
Why?
| Fourier Analysis | 1 | 2019 | 22 | 0.170 |
Why?
| Seizures | 1 | 2021 | 208 | 0.170 |
Why?
| Personal Autonomy | 1 | 2018 | 25 | 0.170 |
Why?
| Socioeconomic Factors | 1 | 2021 | 642 | 0.170 |
Why?
| Ethics, Medical | 1 | 2019 | 45 | 0.160 |
Why?
| Platelet Aggregation Inhibitors | 2 | 2017 | 180 | 0.160 |
Why?
| Vaccination | 1 | 2020 | 294 | 0.160 |
Why?
| Palliative Care | 1 | 2020 | 188 | 0.160 |
Why?
| Wakefulness | 1 | 2018 | 59 | 0.160 |
Why?
| Patient Protection and Affordable Care Act | 1 | 2018 | 61 | 0.160 |
Why?
| Tomography, X-Ray Computed | 3 | 2020 | 1213 | 0.160 |
Why?
| Predictive Value of Tests | 2 | 2019 | 1048 | 0.150 |
Why?
| Young Adult | 4 | 2021 | 4318 | 0.150 |
Why?
| Specialty Boards | 1 | 2017 | 26 | 0.150 |
Why?
| Receptors, Purinergic P2X7 | 2 | 2016 | 6 | 0.150 |
Why?
| Disease Models, Animal | 3 | 2019 | 1639 | 0.150 |
Why?
| Purinergic P2X Receptor Antagonists | 2 | 2016 | 4 | 0.150 |
Why?
| Intracranial Hemorrhages | 1 | 2017 | 41 | 0.150 |
Why?
| Hemodynamics | 1 | 2019 | 290 | 0.150 |
Why?
| Catheterization, Peripheral | 1 | 2018 | 63 | 0.150 |
Why?
| Adolescent | 5 | 2021 | 6897 | 0.150 |
Why?
| Task Performance and Analysis | 1 | 2017 | 61 | 0.150 |
Why?
| Sex Distribution | 2 | 2021 | 158 | 0.150 |
Why?
| Video Recording | 1 | 2017 | 90 | 0.150 |
Why?
| Weight Loss | 2 | 2021 | 271 | 0.150 |
Why?
| Rats, Sprague-Dawley | 4 | 2015 | 1663 | 0.150 |
Why?
| Heart Rate | 1 | 2019 | 357 | 0.150 |
Why?
| Pain | 1 | 2020 | 405 | 0.150 |
Why?
| Prostatectomy | 1 | 2017 | 87 | 0.150 |
Why?
| Dose-Response Relationship, Drug | 1 | 2021 | 1476 | 0.150 |
Why?
| Lacerations | 1 | 2016 | 11 | 0.150 |
Why?
| Robotics | 1 | 2017 | 45 | 0.150 |
Why?
| Tissue and Organ Harvesting | 1 | 2016 | 27 | 0.140 |
Why?
| Linear Models | 1 | 2017 | 309 | 0.140 |
Why?
| Jugular Veins | 1 | 2016 | 35 | 0.140 |
Why?
| Peripheral Nerves | 1 | 2016 | 51 | 0.140 |
Why?
| Craniocerebral Trauma | 1 | 2017 | 89 | 0.140 |
Why?
| Blood Pressure | 1 | 2019 | 587 | 0.140 |
Why?
| Myocytes, Smooth Muscle | 1 | 2016 | 92 | 0.140 |
Why?
| Axons | 2 | 2013 | 43 | 0.130 |
Why?
| Hypothermia | 1 | 2015 | 41 | 0.130 |
Why?
| Models, Educational | 1 | 2015 | 35 | 0.130 |
Why?
| Patient Care Team | 1 | 2017 | 273 | 0.130 |
Why?
| Cell Movement | 1 | 2016 | 271 | 0.130 |
Why?
| Analgesics, Opioid | 1 | 2020 | 501 | 0.130 |
Why?
| Peer Group | 1 | 2015 | 58 | 0.130 |
Why?
| Portal Vein | 1 | 2015 | 30 | 0.130 |
Why?
| Action Potentials | 2 | 2013 | 131 | 0.130 |
Why?
| Emergency Medical Services | 2 | 2015 | 126 | 0.130 |
Why?
| Laparotomy | 1 | 2015 | 36 | 0.130 |
Why?
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 5 | 0.130 |
Why?
| Liver Diseases, Alcoholic | 1 | 2015 | 35 | 0.130 |
Why?
| Diffusion Tensor Imaging | 1 | 2015 | 97 | 0.130 |
Why?
| Nerve Growth Factor | 1 | 2014 | 17 | 0.130 |
Why?
| Extremities | 1 | 2014 | 27 | 0.130 |
Why?
| Torso | 1 | 2014 | 25 | 0.130 |
Why?
| Neurites | 1 | 2014 | 17 | 0.130 |
Why?
| Radiotherapy, Adjuvant | 1 | 2014 | 66 | 0.130 |
Why?
| Cognition | 1 | 2017 | 348 | 0.120 |
Why?
| Intraoperative Complications | 1 | 2015 | 125 | 0.120 |
Why?
| Lymph Node Excision | 1 | 2014 | 140 | 0.120 |
Why?
| Tissue Plasminogen Activator | 1 | 2015 | 124 | 0.120 |
Why?
| Fibrinolytic Agents | 1 | 2015 | 139 | 0.120 |
Why?
| Thrombolytic Therapy | 1 | 2015 | 127 | 0.120 |
Why?
| Disease-Free Survival | 1 | 2014 | 485 | 0.120 |
Why?
| Lymphatic Metastasis | 1 | 2014 | 256 | 0.120 |
Why?
| Venous Thrombosis | 1 | 2015 | 102 | 0.120 |
Why?
| Proportional Hazards Models | 1 | 2014 | 431 | 0.110 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 514 | 0.110 |
Why?
| Microcirculation | 1 | 2013 | 89 | 0.110 |
Why?
| Liver Transplantation | 1 | 2015 | 160 | 0.110 |
Why?
| Leg Injuries | 1 | 2012 | 14 | 0.110 |
Why?
| Infant | 2 | 2019 | 3817 | 0.110 |
Why?
| Surgery Department, Hospital | 1 | 2012 | 6 | 0.110 |
Why?
| Telemedicine | 1 | 2018 | 449 | 0.110 |
Why?
| Skin | 2 | 2013 | 469 | 0.110 |
Why?
| Vascular Grafting | 1 | 2012 | 6 | 0.110 |
Why?
| Tunica Intima | 1 | 2012 | 52 | 0.110 |
Why?
| Neurosurgical Procedures | 1 | 2013 | 120 | 0.110 |
Why?
| Tomography, Optical Coherence | 1 | 2013 | 148 | 0.100 |
Why?
| Rats | 3 | 2016 | 3415 | 0.100 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 1 | 2012 | 46 | 0.100 |
Why?
| Anemia | 1 | 2012 | 84 | 0.100 |
Why?
| Herniorrhaphy | 2 | 2022 | 26 | 0.100 |
Why?
| Neoplasm Staging | 1 | 2014 | 806 | 0.100 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2012 | 82 | 0.100 |
Why?
| Renin-Angiotensin System | 1 | 2012 | 64 | 0.100 |
Why?
| Foot | 1 | 2012 | 50 | 0.100 |
Why?
| Health Resources | 1 | 2012 | 80 | 0.100 |
Why?
| Pulmonary Circulation | 1 | 2011 | 36 | 0.100 |
Why?
| Graft Occlusion, Vascular | 1 | 2012 | 86 | 0.100 |
Why?
| Burns | 1 | 2013 | 170 | 0.100 |
Why?
| Databases as Topic | 2 | 2021 | 46 | 0.100 |
Why?
| Workload | 2 | 2021 | 52 | 0.100 |
Why?
| Behavior, Animal | 1 | 2012 | 200 | 0.100 |
Why?
| Reoperation | 3 | 2021 | 454 | 0.090 |
Why?
| Neoplasm Recurrence, Local | 1 | 2014 | 644 | 0.090 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2011 | 97 | 0.090 |
Why?
| Thrombosis | 1 | 2012 | 243 | 0.090 |
Why?
| Medically Uninsured | 2 | 2020 | 51 | 0.090 |
Why?
| Hyperplasia | 3 | 2016 | 107 | 0.090 |
Why?
| Follow-Up Studies | 1 | 2014 | 2387 | 0.080 |
Why?
| Graft Survival | 3 | 2015 | 165 | 0.080 |
Why?
| Child | 4 | 2023 | 7341 | 0.080 |
Why?
| Coronary Artery Disease | 1 | 2012 | 329 | 0.080 |
Why?
| Anastomosis, Surgical | 2 | 2018 | 72 | 0.070 |
Why?
| Organ Culture Techniques | 2 | 2016 | 53 | 0.060 |
Why?
| Tennessee | 2 | 2015 | 43 | 0.060 |
Why?
| Models, Animal | 2 | 2016 | 255 | 0.060 |
Why?
| Postoperative Hemorrhage | 1 | 2023 | 53 | 0.060 |
Why?
| Intracranial Pressure | 1 | 2022 | 32 | 0.050 |
Why?
| Quarantine | 1 | 2021 | 16 | 0.050 |
Why?
| Cholecystectomy, Laparoscopic | 1 | 2021 | 24 | 0.050 |
Why?
| Age Distribution | 1 | 2021 | 198 | 0.050 |
Why?
| Natural Language Processing | 1 | 2021 | 38 | 0.050 |
Why?
| Hospital Costs | 1 | 2022 | 84 | 0.050 |
Why?
| Violence | 1 | 2021 | 82 | 0.050 |
Why?
| Software | 1 | 2023 | 296 | 0.050 |
Why?
| Information Storage and Retrieval | 1 | 2021 | 64 | 0.050 |
Why?
| National Cancer Institute (U.S.) | 1 | 2020 | 35 | 0.050 |
Why?
| Arterial Pressure | 1 | 2021 | 50 | 0.050 |
Why?
| Coronary Artery Bypass | 2 | 2012 | 134 | 0.050 |
Why?
| Counseling | 1 | 2021 | 149 | 0.050 |
Why?
| Artificial Intelligence | 1 | 2021 | 85 | 0.050 |
Why?
| Feedback | 1 | 2020 | 59 | 0.050 |
Why?
| Propensity Score | 1 | 2020 | 137 | 0.040 |
Why?
| Analysis of Variance | 1 | 2021 | 635 | 0.040 |
Why?
| User-Computer Interface | 1 | 2020 | 93 | 0.040 |
Why?
| Referral and Consultation | 1 | 2022 | 307 | 0.040 |
Why?
| Pulsatile Flow | 1 | 2019 | 18 | 0.040 |
Why?
| Incidence | 1 | 2022 | 1082 | 0.040 |
Why?
| Vascular Access Devices | 1 | 2019 | 29 | 0.040 |
Why?
| Pain Management | 1 | 2020 | 155 | 0.040 |
Why?
| Personnel Staffing and Scheduling | 1 | 2019 | 29 | 0.040 |
Why?
| Limb Salvage | 1 | 2018 | 40 | 0.040 |
Why?
| Veins | 1 | 2019 | 74 | 0.040 |
Why?
| Retreatment | 1 | 2017 | 57 | 0.040 |
Why?
| Infant, Newborn | 2 | 2019 | 2907 | 0.040 |
Why?
| Patient Transfer | 1 | 2018 | 103 | 0.040 |
Why?
| Feasibility Studies | 1 | 2019 | 398 | 0.040 |
Why?
| Time-to-Treatment | 1 | 2018 | 74 | 0.040 |
Why?
| Algorithms | 1 | 2021 | 697 | 0.040 |
Why?
| Learning | 1 | 2018 | 175 | 0.040 |
Why?
| Age Factors | 1 | 2019 | 1198 | 0.030 |
Why?
| Anisotropy | 1 | 2015 | 63 | 0.030 |
Why?
| Recovery of Function | 1 | 2016 | 222 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 684 | 0.030 |
Why?
| Rabbits | 1 | 2016 | 425 | 0.030 |
Why?
| Income | 1 | 2015 | 102 | 0.030 |
Why?
| Statistics as Topic | 1 | 2015 | 103 | 0.030 |
Why?
| Models, Biological | 1 | 2019 | 823 | 0.030 |
Why?
| Chick Embryo | 1 | 2014 | 79 | 0.030 |
Why?
| Chondroitin Sulfate Proteoglycans | 1 | 2014 | 21 | 0.030 |
Why?
| Phlebography | 1 | 2015 | 70 | 0.030 |
Why?
| Vascular Patency | 1 | 2015 | 92 | 0.030 |
Why?
| Lower Extremity | 1 | 2015 | 103 | 0.030 |
Why?
| Surgical Wound Infection | 1 | 2015 | 126 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2020 | 1693 | 0.030 |
Why?
| Ganglia, Spinal | 1 | 2014 | 50 | 0.030 |
Why?
| Residence Characteristics | 1 | 2015 | 166 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 119 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2015 | 231 | 0.030 |
Why?
| Acute Disease | 1 | 2015 | 403 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2014 | 158 | 0.030 |
Why?
| Prognosis | 1 | 2019 | 2118 | 0.030 |
Why?
| Wallerian Degeneration | 1 | 2013 | 1 | 0.030 |
Why?
| Cell Line | 1 | 2016 | 1153 | 0.030 |
Why?
| Sensitivity and Specificity | 1 | 2015 | 923 | 0.030 |
Why?
| Drug Carriers | 1 | 2013 | 81 | 0.030 |
Why?
| Hematocrit | 1 | 2012 | 51 | 0.030 |
Why?
| Microvessels | 1 | 2012 | 34 | 0.030 |
Why?
| Preoperative Period | 1 | 2012 | 59 | 0.030 |
Why?
| Hemoglobins | 1 | 2012 | 126 | 0.030 |
Why?
| Necrosis | 1 | 2012 | 208 | 0.030 |
Why?
| Adenosine Triphosphate | 1 | 2013 | 242 | 0.030 |
Why?
| Cell Proliferation | 1 | 2016 | 1096 | 0.030 |
Why?
| Specialties, Surgical | 1 | 2012 | 38 | 0.030 |
Why?
| Vasodilation | 1 | 2012 | 106 | 0.030 |
Why?
| Motor Activity | 1 | 2013 | 247 | 0.030 |
Why?
| Health Care Surveys | 1 | 2012 | 195 | 0.030 |
Why?
| Wound Healing | 1 | 2013 | 228 | 0.030 |
Why?
| Hemorheology | 1 | 2011 | 14 | 0.030 |
Why?
| Sus scrofa | 1 | 2011 | 39 | 0.020 |
Why?
| Subclavian Artery | 1 | 2011 | 22 | 0.020 |
Why?
| Muscle Contraction | 1 | 2011 | 109 | 0.020 |
Why?
| Preoperative Care | 1 | 2011 | 184 | 0.020 |
Why?
| Animals, Newborn | 1 | 2011 | 396 | 0.020 |
Why?
| Pulmonary Artery | 1 | 2011 | 151 | 0.020 |
Why?
| Blood Vessel Prosthesis Implantation | 1 | 2011 | 129 | 0.020 |
Why?
| Signal Transduction | 1 | 2016 | 1753 | 0.020 |
Why?
| Risk Factors | 1 | 2012 | 3935 | 0.010 |
Why?
|
|
Sexton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|